A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma

Exclusion Criteria

• •1. Pregnant or lactating women
• •2. Female subjects on hormone replacement therapy or hormonal contraceptives
• •3. Suffering from relevant lung diseases (other than asthma) causing impairment in lung function
• •4. Past smoker with a history of ≥10 pack per year or current smoker
• •5. Recent change in the patient's usual asthma treatment
• •6. Patients with risk factors for asthma exacerbation during the study, including (any of the following):
• •* Current requirement for \> 8 puffs per day of reliever medication.
• •* Hospitalization for asthma
• •* Treatment with systemic corticosteroid therapy within 3 months
• •7. Evidence of current or recent neoplastic disease
• •8. Clinically significant cardiovascular, haematological, endocrine, neurological, gastrointestinal, psychiatric, metabolic, immunologic, infectious, hepatic, renal, gynaecological disease or other condition that the investigator considers detrimental to the patient's participation in the study or that may prevent the successful completion of the study
• •9. Positive serology for an infectious disease (including hepatitis B or C) at screening and known case of human immunodeficiency virus \[HIV\]
• •10. Patients who have been hospitalized for any psychiatric illness in the past year, or are diagnosed with major depression
• •11. Clinically significant ECG Abnormality at baseline
• •12. Patients with documented or suspected or current history of alcohol and drug abuse
• •13. Patients who have undergone lung surgery in the previous year
• •14. Participation in an investigational drug trial during 30 days preceding screening